Hypertrophic Cardiomyopathy Clinical Trial
— AOCCOfficial title:
An Integrative-omics Study to Identify New Biomarkers of Cardiomyopathy Patients in China
This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | December 31, 2021 |
Est. primary completion date | July 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Subjects who was diagnosed as cardiomyopathy by medical history, clinical symptoms, laboratory tests including ECG, echocardiography. 2. Subject understands study requirements aand agrees to sign an informed consent form prior to any study procedures. Exclusion Criteria: 1. Endocrine disease known to cause heart muscle disease (including infants of diabetic mothers) 2. History of rheumatic fever 3. Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation, iron overload or heavy metal exposure) 4. HIV infection or born to an HIV positive mother 5. Kawasaki disease 6. Immunologic disease 7. Uremia, active or chronic 8. Abnormal ventricular size or function that can be attributed to intense 9.physical training or chronic anemia 10.Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the onset of arrhythmia (except a patient with chronic arrhythmia, subsequently ablated, whose cardiomyopathy persists after two months is not to be excluded) 11.Malignancy 12.Pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary hypertension) 13.Ischemic coronary vascular disease 14.Association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy |
Country | Name | City | State |
---|---|---|---|
China | Beijing Institute of heart, lung and blood vessel diseases | Beijing | Beijing |
China | Beijing Institute of heart, lung and blood vessel diseases | Beijing | Beijing |
China | Shijie You | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Institute of Heart, Lung and Blood Vessel Diseases | Beijing Anzhen Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy. | The primary objective of this study is to determine whether variation in genetic background or molecules influences clinical outcomes in cardiomyopathy. Differentially expressed molecules are reported in multi-omics. | Five year | |
Secondary | Age for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | gender for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | Height for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | Weight for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | Past medical history for each participant including disease history, surgical history, and family | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | Life style for each participant including smoking history and drinking, specify how many years | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | blood lipids(LDL,HDL,VLDL) | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | creatine | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | urea | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | blood glucose | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | D-dimer | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | hsCRP | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | ||
Secondary | All-cause death | The data is collected during follow-up visit at 1/3/5 years after discharge | One year/Three year/Five year | |
Secondary | Re-hospitalization | Patients are hospitalized due to heart failure with decreasing left ventricular ejection fraction or worsen symptoms. The data is collected during follow-up visit at 1/3/5 years after discharge | One year/Three year/Five year | |
Secondary | Heart transplantation | Patients are underwent heart transplantation due to "pump failure of heart".The data is collected during follow-up visit at 1/3 years after discharge | One year/Three year/Five year | |
Secondary | Malignant arrythmia | Ventricular flutter and fibrillation, atrioventricular block,atrial fibrillation or other cardiac arrhythmia leads to syncope or should be Implantable Cardioverter-Defibrillator (ICD) implantation. | One year/Three year/Five year | |
Secondary | Worsening heart failure | Worsen heart failure is defined as decreased ejection fraction(left ventricular ejection fraction decreased over 10%), left ventricular ejection fraction <45% and enlarged heart size measured by echocardiography and changing level of New York Heart Association (NYHA) Functional Classification.And patients who undergo left ventricular assist device (LVAD) will also be included.The data is collected during follow-up visit at 3/6/9/12/36/60 months after enrollment. | One year/Three year/Five year | |
Secondary | RNA/micro RNA/long-noncoding RNA-sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting | ||
Secondary | Proteomics on Liquid Chromatograph Mass Spectrometer/Mass Spectrometer of plasma sample | The data is collected from lab in an average of 6 month after the sample recruiting | ||
Secondary | Exon sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting | ||
Secondary | Result of echocardiography-Ejection Fraction | The whole results of echocardiography report will be recorded. The indicate can reflect cardiac contraction function and be used for discriminating heart failure or non-heart failure as a main factor. | Three year | |
Secondary | Result of echocardiography-Left Ventricular End Diastolic Diameter | The whole results of echocardiography report will be recorded. The indicate can reflect the size of heart and be used for determination of heart enlargement. | Three year | |
Secondary | Result of echocardiography-E/A Ratio | The whole results of echocardiography report will be recorded. The indicate can reflect diastolic function. | Three year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03249272 -
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
|
Phase 4 | |
Recruiting |
NCT03846297 -
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
|
||
Completed |
NCT02806479 -
Hypertrophic Cardiomyopathy Pilot Study
|
||
Active, not recruiting |
NCT01225978 -
Refining Information Technology Support for Genetics in Medicine
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Enrolling by invitation |
NCT04050579 -
OPIE in the Thin Interventricular Septum
|
N/A | |
Completed |
NCT03537183 -
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
|
N/A | |
Completed |
NCT02590809 -
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
|
Phase 2 | |
Completed |
NCT00001396 -
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
|
Phase 1 | |
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT05135871 -
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT04129905 -
Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT02234336 -
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
Not yet recruiting |
NCT03706001 -
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Not yet recruiting |
NCT04090437 -
HCM-AF Ablation With ACUTUS
|
N/A | |
Completed |
NCT04402268 -
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
|